TABLE 1.
Baseline Characteristics of Patients with NENs (n = 96)
| Characteristic | Data |
|---|---|
| Median age (y) | 66 (range, 34–82) |
| Sex | |
| Female | 39 (41%) |
| Male | 57 (59%) |
| Site of primary tumor | |
| Small intestine | 61 (64%) |
| Pancreas | 15 (16%) |
| Colon | 10 (10%) |
| Lung | 6 (6%) |
| Esophagus | 1 (1%) |
| Stomach | 2 (2%) |
| Rectum | 1 (1%) |
| Metastatic disease | 86 (90%) |
| Liver metastases | 73 (76%) |
| Median Ki-67 | 7 (range, 1–100) |
| WHO grade | |
| NET G1 | 21 (22%) |
| NET G2 | 51 (53%) |
| NET G3 | 9 (9%) |
| NEC | 15 (16%) |
| Median time from diagnosis to uPAR PET/CT (mo) | 25 (range, 0.5–265) |
| Primary tumor resected | 37 (39%) |
| Ongoing treatment at uPAR PET/CT scan time* | |
| Somatostatin analog | 70 (73%) |
| Interferon | 8 (8%) |
| Carboplatin or etoposide | 19 (20%) |
| Capecitabine/5-fluorouracil | 6 (6%) |
| Streptozotocin | 5 (5%) |
| Temozolomide | 2 (2%) |
| Everolimus | 2 (2%) |
| Completed treatment before uPAR PET/CT* | |
| On first line of therapy | 45 (47%) |
| PRRT | 28 (29%) |
| Temozolomide | 6 (6%) |
| Capecitabine/5-fluorouracil | 6 (6%) |
| Streptozotocin | 5 (5%) |
| Carboplatin or etoposide | 10 (10%) |
| Everolimus or sunitinib | 2 (2%) |
| Interferon | 6 (6%) |
| Liver radiofrequency ablation or embolization | 5 (5%) |
| Resection of liver metastases | 4 (4%) |
*
Some patients had received more than one treatment; therefore, number of treatments exceed number of patients.
Data are number followed by percentage in parentheses, unless otherwise indicated. Percentages were rounded and may not add up to 100%.